Developer docs
API playgroundTry for free, no card

Search company profiles

Ananda Pharma

Full company profile

uuid000f5ee

Namestring
Ananda Pharma
Legal namestring
Ananda Pharma GmbH
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Ananda Pharma is a clinical-stage biopharmaceutical company developing non-psychoactive CBD-based therapeutics. Its lead asset, MRX1 CBD Oral Solution, is being advanced through clinical trials for two indications: endometriosis-associated pain (targeting ~190 million women globally) and chemotherapy-induced peripheral neuropathy (CIPN). The company completed a Phase 1 pharmacokinetic study in June 2026 demonstrating favorable safety and tolerability across two dose levels, with all treatment-emergent adverse events classified as mild and no serious events reported. In March 2026, Ananda received MHRA and NHS Health Research Authority Ethics Committee approval to initiate the ENDOCAN Phase 2 trial, which will randomize up to 100 women over a 12-week treatment period across NHS Lothian and NHS Grampian in Scotland, with Phase 2 dosing planned for H2 2026.

The company is pre-revenue and operates a pharmaceutical drug development and commercialization model, with future revenue contingent on regulatory approval and commercial launch in endometriosis pain and CIPN indications. Its underlying technology centers on a proprietary high-dose CBD oral solution formulation. The company also holds SME (small or medium-sized enterprise) qualification at the European Medicines Agency (EMA) in London and has received development funding from the European Union through the European Regional Development Fund (Europäischer Fonds für Regionale Entwicklung). Following the April 2026 U.S. rescheduling of FDA-approved cannabis medicines from Schedule I to Schedule III — which facilitates easier banking access — Ananda is preparing to raise $10–20 million in private funding to accelerate U.S. regulatory engagement and manufacturing. Leadership is anchored by Managing Director (Geschäftsführer) Yatin Shah, and clinical operations are run through NHS partnerships rather than a commercial sales force.

Note: Source data references two entities sharing the Ananda Pharma name — Ananda Pharma GmbH (Potsdam, Germany; HRB 26894), focused on diagnostic tests and sustainable cultivation of pharmaceutically usable plants, and the UK-based biopharmaceutical entity advancing MRX1 through clinical trials. The dominant investment narrative is the UK biopharmaceutical entity, but the corporate structure should be verified.

Short descriptiontext

Ananda Pharma is a clinical-stage biopharmaceutical company developing MRX1, a proprietary non-psychoactive CBD oral solution for endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. Pre-revenue, the UK-based company is preparing a $10–20 million private funding round to advance U.S. regulatory and manufacturing scale-up.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid drug development, CBD oral solutions, clinical-stage biopharmaceuticals, endometriosis pain therapy, peripheral neuropathy treatment
Industry3 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage company developing proprietary CBD-based therapeutic. Revenue will be generated from drug commercialization upon regulatory approval for endometriosis pain and chemotherapy-induced peripheral neuropathy indications.

ca.finance.yahoo.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ananda Pharma develops innovative therapeutics through proprietary CBD oral solution formulations (lead asset MRX1) targeting endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. The company also develops diagnostic medical devices and pursues sustainable cultivation of pharmaceutically usable plants. It is qualified as an SME at the European Medicines Agency and is advancing its lead asset through Phase 2 clinical trials.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ananda Pharma is a UK-based biopharmaceutical company focused on developing innovative CBD-based medicines. The company's primary product is MRX1 CBD Oral Solution, a proprietary non-psychoactive CBD drug formulation. Currently, Ananda Pharma is advancing MRX1 through clinical development, with an ENDOCAN Phase 2 clinical trial approved for investigating the drug's efficacy for endometriosis pain, and plans for Phase 2 trials targeting chemotherapy-induced peripheral neuropathy. The company operates with a mission to address unmet medical needs in chronic pain conditions through cannabis-derived therapeutics.

Product and service2 records
1MRX1 CBD Oral Solution
CategoryPharmaceutical Drug Development
Description

Proprietary non-psychoactive CBD (cannabidiol) oral solution developed for the treatment of endometriosis-associated pain and chemotherapy-induced peripheral neuropathy; targets chronic pain indications with significant unmet medical need and has completed Phase 1 with a favorable safety profile.

2Diagnostic Medical Devices and Tests
CategoryDiagnostics
Description

Diagnostic medical devices and tests being developed alongside drug formulations by Ananda Pharma GmbH for pharmaceutical and clinical applications.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

NHS Lothian is conducting the Phase 2 ENDOCAN clinical trial for MRX1 CBD oral solution targeting endometriosis-associated pain. The trial will randomize women over a 12-week treatment period.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

NHS Grampian is conducting the Phase 2 ENDOCAN clinical trial for MRX1 CBD oral solution targeting endometriosis-associated pain. The trial is part of the ENDOCAN Phase 2 clinical program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jazz Pharmaceuticals owns GW Pharmaceuticals, which developed Epidiolex, the first FDA-approved CBD prescription drug. Ananda's MRX1 CBD oral solution follows the same cannabinoid pharmaceutical model, targeting specific indications in the regulatory pathway GW pioneered.

TypeDirect peer
Description

Clinical-stage cannabinoid therapeutics company developing transdermal CBD (ZYN002) for indications including Fragile X syndrome and other CNS conditions. Direct peer as a CBD-based pharmaceutical targeting unmet medical needs via the regulatory pathway.

TypeDirect peer
Description

Cannabinoid pharmaceutical-focused biotech developing proprietary cannabinoid APIs (INM-901) for neurological and dermatological indications. Comparable in being a small, pre-commercial cannabinoid pharma pursuing the regulated drug approval route.

4Botanix Pharmaceuticals
TypeDirect peer
Description

Clinical-stage cannabinoid pharmaceutical company developing prescription therapeutics (e.g., BTX 1801, BTX 1703) for dermatology and antimicrobial indications. Direct peer in clinical-stage cannabinoid drug development targeting regulated prescription markets.

TypeEmerging player
Description

Developer of Myfembree (relugolix combination) approved for endometriosis-associated pain. Direct comparator for Ananda's lead indication; differs in mechanism but competes for the same physician and patient population.

TypeBroad incumbent
Description

Marketer of Orilissa (elagolix), the first FDA-approved oral GnRH antagonist for endometriosis pain. Larger pharma incumbent in Ananda's lead indication, defining the standard of care Ananda would compete against.

7Tilray Brands
TypeBroad incumbent
Description

Major global cannabis company with a growing pharmaceutical/medical division. Broad incumbent in cannabis therapeutics and a likely competitor for any Ananda commercial partnership or distribution arrangement.

TypeBroad incumbent
Description

Large cannabis company with medical/pharmaceutical product lines (e.g., Spectrum Therapeutics). Broad incumbent that develops and distributes cannabinoid-based therapeutics, providing scale comparison for Ananda's niche CBD pharma strategy.

TypeBroad incumbent
Description

Vertically integrated CBD therapeutics company with a broad hemp-derived CBD product portfolio focused on wellness and clinical indications (e.g., seizure disorders, sleep, pain). Comparable as a CBD-focused therapeutic brand pursuing clinical substantiation.

TypeBroad incumbent
Description

Global cannabinoid company with pharmaceutical partnerships (e.g., with Ginkgo Bioworks) and consumer CBD products. Broad incumbent investing in cannabinoid pharmaceutical science, relevant as a larger-scale counterpart in regulated cannabis-based therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ananda Pharma

Pharmaceutical Drug Developmentanandapharma.com

Ananda Pharma is a clinical-stage biopharmaceutical company developing MRX1, a proprietary non-psychoactive CBD oral solution for endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. Pre-revenue, the UK-based company is preparing a $10–20 million private funding round to advance U.S. regulatory and manufacturing scale-up.

What Ananda Pharma does

Ananda Pharma is a clinical-stage biopharmaceutical company developing non-psychoactive CBD-based therapeutics. Its lead asset, MRX1 CBD Oral Solution, is being advanced through clinical trials for two indications: endometriosis-associated pain (targeting ~190 million women globally) and chemotherapy-induced peripheral neuropathy (CIPN). The company completed a Phase 1 pharmacokinetic study in June 2026 demonstrating favorable safety and tolerability across two dose levels, with all treatment-emergent adverse events classified as mild and no serious events reported. In March 2026, Ananda received MHRA and NHS Health Research Authority Ethics Committee approval to initiate the ENDOCAN Phase 2 trial, which will randomize up to 100 women over a 12-week treatment period across NHS Lothian and NHS Grampian in Scotland, with Phase 2 dosing planned for H2 2026.

The company is pre-revenue and operates a pharmaceutical drug development and commercialization model, with future revenue contingent on regulatory approval and commercial launch in endometriosis pain and CIPN indications. Its underlying technology centers on a proprietary high-dose CBD oral solution formulation. The company also holds SME (small or medium-sized enterprise) qualification at the European Medicines Agency (EMA) in London and has received development funding from the European Union through the European Regional Development Fund (Europäischer Fonds für Regionale Entwicklung). Following the April 2026 U.S. rescheduling of FDA-approved cannabis medicines from Schedule I to Schedule III — which facilitates easier banking access — Ananda is preparing to raise $10–20 million in private funding to accelerate U.S. regulatory engagement and manufacturing. Leadership is anchored by Managing Director (Geschäftsführer) Yatin Shah, and clinical operations are run through NHS partnerships rather than a commercial sales force.

Note: Source data references two entities sharing the Ananda Pharma name — Ananda Pharma GmbH (Potsdam, Germany; HRB 26894), focused on diagnostic tests and sustainable cultivation of pharmaceutically usable plants, and the UK-based biopharmaceutical entity advancing MRX1 through clinical trials. The dominant investment narrative is the UK biopharmaceutical entity, but the corporate structure should be verified.

Ananda Pharma firmographics

Firmographics
Name
Ananda Pharma
Legal name
Ananda Pharma GmbH
Website
https://anandapharma.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Ananda Pharma is a clinical-stage biopharmaceutical company developing MRX1, a proprietary non-psychoactive CBD oral solution for endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. Pre-revenue, the UK-based company is preparing a $10–20 million private funding round to advance U.S. regulatory and manufacturing scale-up.
Ownership category
akta.pro rank

Ananda Pharma industry classification

Industry
Product category
Pharmaceutical Drug Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cannabinoid drug development
  • CBD oral solutions
  • Clinical-stage biopharmaceuticals
  • Endometriosis pain therapy
  • Peripheral neuropathy treatment

Where Ananda Pharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Ananda Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical stage company developing proprietary CBD-based therapeutic. Revenue will be generated from drug commercialization upon regulatory approval for endometriosis pain and chemotherapy-induced peripheral neuropathy indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Ananda Pharma product offering

Product offering

Core offering

Ananda Pharma develops innovative therapeutics through proprietary CBD oral solution formulations (lead asset MRX1) targeting endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. The company also develops diagnostic medical devices and pursues sustainable cultivation of pharmaceutically usable plants. It is qualified as an SME at the European Medicines Agency and is advancing its lead asset through Phase 2 clinical trials.

Product overview

Ananda Pharma is a UK-based biopharmaceutical company focused on developing innovative CBD-based medicines. The company's primary product is MRX1 CBD Oral Solution, a proprietary non-psychoactive CBD drug formulation. Currently, Ananda Pharma is advancing MRX1 through clinical development, with an ENDOCAN Phase 2 clinical trial approved for investigating the drug's efficacy for endometriosis pain, and plans for Phase 2 trials targeting chemotherapy-induced peripheral neuropathy. The company operates with a mission to address unmet medical needs in chronic pain conditions through cannabis-derived therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • MRX1 CBD Oral Solution Proprietary non-psychoactive CBD (cannabidiol) oral solution developed for the treatment of endometriosis-associated pain and chemotherapy-induced peripheral neuropathy; targets chronic pain indications with significant unmet medical need and has completed Phase 1 with a favorable safety profile.
  • Diagnostic Medical Devices and Tests Diagnostic medical devices and tests being developed alongside drug formulations by Ananda Pharma GmbH for pharmaceutical and clinical applications.

Companies that use Ananda Pharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Ananda Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Ananda Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • NHS LothiancoreStrategic or Co-development Partner · 4 March 2026NHS Lothian is conducting the Phase 2 ENDOCAN clinical trial for MRX1 CBD oral solution targeting endometriosis-associated pain. The trial will randomize women over a 12-week treatment period.
  • NHS GrampiancoreStrategic or Co-development Partner · 4 March 2026NHS Grampian is conducting the Phase 2 ENDOCAN clinical trial for MRX1 CBD oral solution targeting endometriosis-associated pain. The trial is part of the ENDOCAN Phase 2 clinical program.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Ananda Pharma competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals (GW Pharmaceuticals): Jazz Pharmaceuticals owns GW Pharmaceuticals, which developed Epidiolex, the first FDA-approved CBD prescription drug. Ananda's MRX1 CBD oral solution follows the same cannabinoid pharmaceutical model, targeting specific indications in the regulatory pathway GW pioneered.
  • Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics company developing transdermal CBD (ZYN002) for indications including Fragile X syndrome and other CNS conditions. Direct peer as a CBD-based pharmaceutical targeting unmet medical needs via the regulatory pathway.
  • InMed Pharmaceuticals: Cannabinoid pharmaceutical-focused biotech developing proprietary cannabinoid APIs (INM-901) for neurological and dermatological indications. Comparable in being a small, pre-commercial cannabinoid pharma pursuing the regulated drug approval route.
  • Botanix Pharmaceuticals: Clinical-stage cannabinoid pharmaceutical company developing prescription therapeutics (e.g., BTX 1801, BTX 1703) for dermatology and antimicrobial indications. Direct peer in clinical-stage cannabinoid drug development targeting regulated prescription markets.

Emerging players

  • Myovant Sciences (Sumitomo Pharma): Developer of Myfembree (relugolix combination) approved for endometriosis-associated pain. Direct comparator for Ananda's lead indication; differs in mechanism but competes for the same physician and patient population.

Broad incumbents

  • AbbVie: Marketer of Orilissa (elagolix), the first FDA-approved oral GnRH antagonist for endometriosis pain. Larger pharma incumbent in Ananda's lead indication, defining the standard of care Ananda would compete against.
  • Tilray Brands: Major global cannabis company with a growing pharmaceutical/medical division. Broad incumbent in cannabis therapeutics and a likely competitor for any Ananda commercial partnership or distribution arrangement.
  • Canopy Growth Corporation: Large cannabis company with medical/pharmaceutical product lines (e.g., Spectrum Therapeutics). Broad incumbent that develops and distributes cannabinoid-based therapeutics, providing scale comparison for Ananda's niche CBD pharma strategy.
  • Charlottes Web Holdings: Vertically integrated CBD therapeutics company with a broad hemp-derived CBD product portfolio focused on wellness and clinical indications (e.g., seizure disorders, sleep, pain). Comparable as a CBD-focused therapeutic brand pursuing clinical substantiation.
  • Cronos Group: Global cannabinoid company with pharmaceutical partnerships (e.g., with Ginkgo Bioworks) and consumer CBD products. Broad incumbent investing in cannabinoid pharmaceutical science, relevant as a larger-scale counterpart in regulated cannabis-based therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Ananda Pharma social profiles

Digital presence

Ananda Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ananda Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Ananda Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ananda Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ananda Pharma

What does Ananda Pharma do?

Ananda Pharma develops innovative therapeutics through proprietary CBD oral solution formulations (lead asset MRX1) targeting endometriosis-associated pain and chemotherapy-induced peripheral neuropathy. The company also develops diagnostic medical devices and pursues sustainable cultivation of pharmaceutically usable plants. It is qualified as an SME at the European Medicines Agency and is advancing its lead asset through Phase 2 clinical trials.

Is Ananda Pharma a public or private company?

Ananda Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ananda Pharma founded?

Ananda Pharma was founded in -1. It employs 1 to 10 people.

Where is Ananda Pharma based?

Ananda Pharma is headquartered in London, United Kingdom, in the Europe region.

How does Ananda Pharma make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are Ananda Pharma's main competitors?

Direct peers on record are Jazz Pharmaceuticals (GW Pharmaceuticals), Zynerba Pharmaceuticals, InMed Pharmaceuticals and Botanix Pharmaceuticals. Myovant Sciences (Sumitomo Pharma) is listed as an emerging player. Broad incumbents are AbbVie, Tilray Brands, Canopy Growth Corporation, Charlottes Web Holdings and Cronos Group.

Does Ananda Pharma have an API?

No public API is recorded for Ananda Pharma.

What industry is Ananda Pharma in?

Ananda Pharma's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CannabishealthnewsAnanda Pharma Doses First Patient in NIHR-Backed CIPN TrialAnanda Pharma has dosed the first patient in the ACTiON trial, a Phase 2 study funded by the NIHR evaluating its proprietary CBD-based oral solution MRX1 for chemotherapy-induced peripheral neuropathy. The trial addresses a significant unmet need in oncology supportive care, as CIPN affects approximately 67% of patients undergoing neurotoxic chemotherapy and often forces dose reductions.AijournFirst Patient Dosed in Chemotherapy Induced Peripheral Neuropathy Clinical TrialAnanda Pharma Limited has dosed the first patient in the ACTiON Phase 2 clinical trial investigating MRX1, its proprietary CBD-based drug candidate, for treating Chemotherapy Induced Peripheral Neuropathy. The double-blind, placebo-controlled crossover trial, led by Professor Marie Fallon of the University of Edinburgh and funded by the National Institute for Health and Care Research, targets enrollment of 92 participants. CIPN affects over 140,000 new patients annually in the UK alone with no effective therapies currently available, representing a significant unmet medical need that can force chemotherapy dose reductions.PR NewswireFirst Patient Dosed in Chemotherapy Induced Peripheral Neuropathy Clinical TrialAnanda Pharma Limited announced the first patient has been dosed in the ACTiON Phase 2 clinical trial investigating MRX1, its proprietary CBD-based drug candidate, for treating Chemotherapy Induced Peripheral Neuropathy (CIPN). The trial, led by Professor Marie Fallon of the University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR), is a double-blind, placebo-controlled, crossover study targeting enrollment of 92 participants. CIPN affects over 140,000 new patients annually in the UK and approximately 400,000 in the US at an annual healthcare cost of $2.5bn, with no effective therapies currently available.PR NewswireFirst Patient Dosed in Chemotherapy Induced Peripheral Neuropathy Clinical TrialAnanda Pharma announced the first patient has been dosed in its ACTiON trial for chemotherapy-induced peripheral neuropathy (CIPN). The Phase 2, double-blind, placebo-controlled crossover study, led by Professor Marie Fallon, targets 92 participants and assesses MRX1's efficacy and safety. CIPN affects over 140,000 new UK cases annually with no effective therapies.MorningstarFirst Patient Dosed in Chemotherapy Induced Peripheral Neuropathy Clinical TrialAnanda Pharma announced the first patient has been dosed in its ACTiON clinical trial for chemotherapy-induced peripheral neuropathy (CIPN). The Phase 2, double-blind, placebo-controlled crossover study, led by Professor Marie Fallon, targets 92 participants and assesses MRX1's efficacy and safety. CIPN affects over 140,000 new UK cases annually with no effective therapies.PR NewswireMRX1 Successfully Delivered to Clinical Trial SiteAnanda Pharma Limited has delivered its MRX1 investigational product to the University of Edinburgh's central pharmacy to support the initiation of the ACTiON Phase 2 clinical trial for chemotherapy-induced peripheral neuropathy (CIPN). The milestone brings the company closer to dosing its first Phase 2 patient following successful completion of its first in-human study earlier this year. The trial, led by Professor Marie Fallon with 92 participants enrolled in a double-blind, placebo-controlled crossover study, is funded by the National Institute for Health and Care Research.MorningstarMRX1 Successfully Delivered to Clinical Trial SiteAnanda Pharma delivered MRX1 to the University of Edinburgh to support the ACTiON Phase 2 trial for chemotherapy-induced peripheral neuropathy. The trial, led by Professor Marie Fallon, targets 92 participants and follows a successful first-in-human study. First participant first dose is pending.GlobeNewswireEndometriosis Global Clinical Trials Market Review Report 2026: Region, Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor TypeResearchAndMarkets published a 2026 global clinical trials review on endometriosis, covering trial numbers, enrollment, regions, phases, and sponsor types. The report includes recent news such as BioInvent's Phase 3 milestone and other company updates, and lists major companies like AbbVie and Bayer.HarianbasisUS Rescheduling Moves Boost Funding Prospects for Cannabis MedicineThe U.S. Department of Justice moved last week to reschedule FDA-approved cannabis medicines and state-regulated medical marijuana products, a regulatory shift that facilitates easier banking access and allows companies to claim tax credits previously unavailable to the industry. Ananda Pharma is planning to secure $10–20 million in private funding within six months to develop a non-psychoactive CBD drug for endometriosis pain, while IGC Pharma is considering a $50 million fundraising round for its mid-stage low-dose THC liquid targeting Alzheimer's disease symptoms. Industry analysts and legal experts suggest the reclassification could remove longstanding stigma that deterred mainstream financial institutions, potentially unlocking capital flows across the cannabis therapeutics sector.MMJDailyCompanies with cannabis-based drugs eye IPOs, private funding boost after US reclassificationThe U.S. Department of Justice rescheduled FDA-approved cannabis medicines and state-regulated medical marijuana products, making it easier for companies to bank and receive tax credits and deductions. Companies developing cannabis-based drugs, including Ananda Pharma which is preparing to raise $10–20 million in private funding, say the rescheduling could unlock private capital and public market access by reducing stigma among mainstream investors and financial institutions.